BrightHeart, a Paris-based company developing AI for prenatal ultrasound, has raised €11 million in Series A funding. The round was co-led by Odyssée Venture and GO Capital, with participation from the Mussallem CHD Alliance, Lift Value, IDAHO HealthTech Club via Side Angels, and founding investor Sofinnova Partners.
Angel investors in the round include Professor Laurent Salomon, former President of the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG), and serial medtech entrepreneurs Sacha Loiseau and John Gridley.
The funding will support U.S. commercialization, expansion across Europe, and continued product development. BrightHeart’s platform integrates into routine ultrasound workflows to support detection of congenital heart defects (CHD), the most common type of birth defect globally.
“This new round of funding empowers us to accelerate BrightHeart’s mission of making AI the new standard of care in prenatal ultrasound,” said Cécile Dupont, CEO of BrightHeart and Partner at Sofinnova Partners. “Our goal is to enhance diagnostic accuracy, improve outcomes for families and babies, and streamline clinical workflows for healthcare professionals. We are thrilled to have the support of our investors, who bring not only deep expertise in healthcare innovation but also proven experience in scaling companies globally.”
In 2025, BrightHeart achieved five FDA clearances and published two peer-reviewed studies in Obstetrics & Gynecology. The company says its technology has been clinically validated to improve CHD detection to over 96%.
“BrightHeart has built a defensible clinical foundation in one of the most complex areas of prenatal imaging,” said Julien Andrieux, partner at Odyssée Venture. Leïla Nicolas, partner at GO Capital, added: “By pairing expert-level screening with tangible workflow benefits and seamless integration, the company is well positioned to become a reference platform in prenatal ultrasound.”
The participation of the Mussallem CHD Alliance, a foundation focused on congenital heart defects, reflects growing interest in improving prenatal CHD detection rates, which remain low despite CHD being the most common birth defect.
“At the Mussallem CHD Alliance, we envision a future where babies born with congenital heart defects have access to early and accurate diagnosis, and BrightHeart’s platform gives us confidence that this future is within reach,” said Orin Herskowitz, President of the Mussallem CHD Alliance. “By embedding advanced AI directly into ultrasound workflows, BrightHeart is paving the way for expert-level fetal heart screening to become part of routine prenatal care.”
BrightHeart is part of Sofinnova MD Start, Sofinnova Partners’ medical device accelerator.
